Get notified when TSHA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Fraud / investigation

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Sec Investigation (new) — Subpoenas received late 2024 regarding August 2023 private placement and public offerings; document production completed April 2025, though investigation is not a determination of wrongdoing.
NASDAQ: TSHA Taysha Gene Therapies, Inc. 10-K

Taysha doses pivotal Rett trial patients, raises $264M, as Astellas option expires

Filed March 19, 2026 · Period ending December 31, 2025 · Compared to 10-K Feb 26, 2025 · ~2 min read

Key Changes

  • high

    Multiple patients dosed in REVEAL pivotal trial (first Q4 2025); FDA aligned on 6-month interim analysis for BLA submission; Breakthrough Therapy designation granted September 2025; all 12 Part A patients gained/regained developmental milestones with no serious adverse events.

    Business: TSHA-102 Clinical Progress verify on EDGAR →
  • high

    Raised $264M in 2025 ($215.6M May equity offering, $48.4M ATM sales) and refinanced debt with new $50M term loan (up to $100M available); cash runway extended from Q4 2026 to 2028; net loss increased 22% to $109M.

    MD&A: Capital Raises & Liquidity verify on EDGAR →
  • high

    Astellas Rett Option expired October 2025 without exercise; company retains full economic rights to TSHA-102 but bears all development and commercialization costs. Abeona CLN1 Agreement terminated February 2026.

    MD&A: Partnership Changes verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.

Partner

Trade TSHA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify